×

Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

  • US 9,993,539 B2
  • Filed: 06/29/2017
  • Issued: 06/12/2018
  • Est. Priority Date: 08/05/2015
  • Status: Active Grant
First Claim
Patent Images

1. A method of eliciting an immune response in a patient who has liver cancer (HCC), breast cancer (BRCA), melanoma, and/or uterine cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells that aberrantly express a peptide in the patient, wherein said peptide consists of the amino acid sequence of SMLGEEIQL (SEQ ID NO:

  • 2), wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×